Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
182.30
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biogen Idec
< Previous
1
2
3
4
5
6
7
8
9
...
47
48
Next >
After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study
October 08, 2024
Sage Therapeutics' dalzanemdor failed to show significant results in Phase 2 Alzheimer's study. The company discontinues Alzheimer's development but expects Huntington's data soon. Stock drops 10.7%.
Via
Benzinga
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
October 08, 2024
From
Biogen Inc.
Via
GlobeNewswire
Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year
October 07, 2024
Scholar Rock's Phase 3 SAPPHIRE trial for apitegromab in spinal muscular atrophy met its primary endpoint, showing statistically significant motor function improvements and favorable outcomes compared...
Via
Benzinga
Exposures
Product Safety
Looking Into Biogen's Recent Short Interest
October 03, 2024
Via
Benzinga
Forecasting The Future: 20 Analyst Projections For Biogen
September 23, 2024
Via
Benzinga
Key Takeaways From Biogen Analyst Ratings
September 04, 2024
Via
Benzinga
Cracking The Code: Understanding Analyst Reviews For Biogen
August 19, 2024
Via
Benzinga
1 Unstoppable Growth Stock Heading to $2 Trillion by 2030
September 28, 2024
It's hard to bet against this company right now.
Via
The Motley Fool
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate
September 26, 2024
Sage Therapeutics announced Biogen's decision to terminate their collaboration on SAGE-324 following negative results from a Phase 2 study, with Sage resuming full ownership of the asset by February...
Via
Benzinga
Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial
September 24, 2024
UCB and Biogen announced positive Phase 3 results for dapirolizumab pegol in treating moderate-to-severe systemic lupus erythematosus, showing significant improvement in disease activity after 48...
Via
Benzinga
UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
September 24, 2024
From
Biogen Inc.
Via
GlobeNewswire
How Is The Market Feeling About Biogen?
August 09, 2024
Via
Benzinga
Biogen Board Appoints Two New Independent Directors
September 12, 2024
Dr. Lloyd Minor and Prof Sir Menelas Pangalos bring significant scientific expertise and considerable experience in medicine research and development
From
Biogen Inc.
Via
GlobeNewswire
Zepbound And Mounjaro Maker Eli Illy Has A New CFO As It Navigates Regulatory Challenges: What You Should Know
September 09, 2024
Eli Lilly and Company has appointed Lucas Montarce as executive vice president and chief financial officer, effective immediately.
Via
Benzinga
Bernie Sanders Says If You're Poor In America You'll Live 10-15 Years Less: 'Anybody Else See A Problem With That?'
September 09, 2024
Via
Benzinga
Biogen/Eisai's Leqembi Brings Hope To Early Alzheimer's Patients Amid Logistical Challenges
September 09, 2024
Biogen's Leqembi offers hope for Alzheimer's patients by slowing cognitive decline. Patients like Missie Meeks highlight the benefits, but challenges with side effects, insurance, and diagnostics...
Via
Benzinga
Biogen's Higher Dose Spinraza Shows To Slow Neurodegeneration Faster In Infants With Rare Neuromuscular Disorder
September 04, 2024
Biogen announced topline data from the Phase 2/3 DEVOTE study showing a higher dose of nusinersen significantly improves motor function in treatment-naïve infants with spinal muscular atrophy, compared...
Via
Benzinga
Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA
September 04, 2024
From
Biogen Inc.
Via
GlobeNewswire
These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now
August 31, 2024
This competitive showdown just saw one of the players hit a couple of bumps.
Via
The Motley Fool
Eli Lilly Is The Nvidia Of Weight Loss And GLP-1 Space, Says Roundhill Investments CEO, Emphasizes Market Leadership And Growth Potential Of Zepbound Maker
August 28, 2024
Roundhill Investments CEO Dave Mazza compared Eli Lilly And Co to Nvidia in the weight loss and GLP-1 space.
Via
Benzinga
Chinese E-Commerce Giant Drops 35% In 2 Days, But Analysts See 92% Upside Potential
August 27, 2024
PDD Holdings Inc. (NASDAQ: PDD) saw a 29% drop after disappointing Q2 results, but analysts remain bullish with price targets ranging from $84 to $185.
Via
Benzinga
Eli Lilly's Alzheimer's Drug Faces UK Agency Block After Biogen's Medicine Rejection Over Cost, Safety
August 26, 2024
The NHS is expected to block the Alzheimer's drug donanemab due to safety risks and high costs following NICE's recent rejection of Biogen's lecanemab, leaving campaigners and experts disappointed.
Via
Benzinga
Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement
August 22, 2024
The U.K.'s Medicines and Healthcare products Regulatory Agency approved Eisai and Biogen's Leqembi for treating mild cognitive impairment and mild dementia due to Alzheimer's. Despite this, NICE stated...
Via
Benzinga
New Study Reveals How Classical Music Could Revolutionize Depression Care
August 12, 2024
In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of...
Via
PressReach
Exposures
Product Safety
A Blood Test Could Detect Early Alzheimer's. That Could Make These 2 Stocks Red-Hot Buys.
August 11, 2024
These companies have approved Alzheimer's treatments that could generate billions in revenue for their respective businesses.
Via
The Motley Fool
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032
August 09, 2024
EQNX::TICKER_START (NYSE:OGEN),(NYSE:ABT),(NASDAQ:BIIB),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END
Via
FinancialNewsMedia
Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review
August 02, 2024
Apple and Meta had strong results, while AI spending remains robust.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Biogen (BIIB) Q2 2024 Earnings Call Transcript
August 01, 2024
BIIB earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday?
August 01, 2024
Markets experienced a sharp downturn, driven by heightened geopolitical tensions and economic uncertainties that negatively impacted investor risk sentiment, just a day after the Federal Open Market...
Via
Benzinga
Biogen Q2 Earnings: Beats Consensus, Lifts 2024 Profit Forecast As New Drug Launches Expected To Offset Decline In Multiple Sclerosis Med Sales
August 01, 2024
Biogen reported Q2 adjusted EPS of $5.28, surpassing the $4.03 consensus. Sales were $2.47 billion, narrowly beating the $2.38 billion consensus. Notable changes include a 5% drop in multiple sclerosis...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
47
48
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.